Salud financiera de hoja de balance de Rallybio

Salud financiera controles de criterios 5/6

Rallybio tiene un patrimonio de los accionistas total de $106.2M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $115.6M y $9.4M respectivamente.

Información clave

0.4%

Ratio deuda-patrimonio

US$392.00k

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$109.93m
Patrimonio	US$106.18m
Total pasivo	US$9.44m
Activos totales	US$115.62m

Actualizaciones recientes sobre salud financiera

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Jan 04

Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

Sep 19

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

May 15

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Jan 30

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Oct 31

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Jul 07

Recent updates

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Jan 04

Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

Sep 19

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

May 15

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Jan 30

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Oct 31

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Jul 07

Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans

Mar 16

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($114.8M) de RLYB superan a sus pasivos a corto plazo ($9.3M).

Pasivo a largo plazo: Los activos a corto plazo de RLYB ($114.8M) superan a sus pasivos a largo plazo ($173.0K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: RLYB tiene más efectivo que su deuda total.

Reducción de la deuda: No se dispone de datos suficientes para determinar si el ratio deuda-patrimonio de RLYB se ha reducido en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: RLYB tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: RLYB dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 28.3% cada año

Salud financiera de hoja de balance de Rallybio

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Recent updates

Ralebio Corporation Announces the Presentation of Results from FNAIT Systematic Literature Review and Meta- Analysis At the Academy of Managed Care Pharmacy 2024 Annual Meeting

Rallybio Corporation, Annual General Meeting, May 15, 2024

Rallybio Corporation announced that it has received $6.599999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Price target decreased by 32% to US$9.38

Rallybio Corporation Announces the Prioritization of Its Portfolio and a 45% Workforce Reduction to Focus Resources on Its Phase 2-Ready Clinical Stage Programs

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Rallybio Corporation Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116

Rallybio Corporation Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212

New major risk - Share price stability

New minor risk - Market cap size

Rallybio Corporation Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

Rallybio Corporation Presents Phase 1 Single Ascending Dose Data for RLYB116, Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Price target decreased by 7.3% to US$16.83

Rallybio Corporation Announces Executive Changes

Rallybio Corporation Reports Data from the Phase 1b Proof-Of-Concept Study of RLYB212

Price target decreased by 9.9% to US$18.17

Rallybio to Present Data from the RLYB212 Phase 1b Proof-Of-Concept Study

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Price target decreased by 7.2% to US$22.50

Rallybio Corporation Announces Chief Financial Officer Changes

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Rallybio Announces Publication of Data Highlighting the Ability of HPA-1A-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT

Price target decreased to US$28.00

High number of new directors

Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Price target increased to US$30.67

Rallybio Corporation Expects to Discuss the Preliminary Platelet Elimination Data by the End of the Third Quarter of 2022

Rallybio Corporation Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Rallybio Corporation Announces Retirement of Jeffrey Fryer as Chief Financial Officer

High number of new directors

Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi

High number of new directors

Rallybio Corporation, Annual General Meeting, May 24, 2022

High number of new directors

Rallybio Corporation Announces Board Changes

Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans

CEO & Chairman recently bought US$103k worth of stock

High number of new directors

Rallybio Corporation Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera